Researcher
Carolien Eggermont
- Keywords:Medicine
- Disciplines:Social sciences
Affiliations
- Laboratory for Medical and Molecular Oncology (Research group)
Member
From22 Mar 2021 → Today - Faculty of Medicine and Pharmacy (Faculty)
Member
From22 Aug 2016 → Today - Clinical sciences (Department)
Member
From1 Oct 2017 → Today - Clinical sciences (Department)
Member
From1 Oct 2016 → 20 Oct 2022 - Faculty of Medicine and Pharmacy (Faculty)
Member
From13 Aug 2014 → 21 Jun 2016
Publications
1 - 5 of 5
- Inhibition of PLK1 Destabilizes EGFR and Sensitizes EGFR-Mutated Lung Cancer Cells to Small Molecule Inhibitor Osimertinib(2023)
Authors: Carolien Eggermont, Gustavo Gutierrez Gonzalez, Jacques De Grève, Philippe Giron
- The EGFR-STYK1-FGF1 axis sustains functional drug tolerance to EGFR inhibitors in EGFR-mutant non-small cell lung cancer(2022)
Authors: Carolien Eggermont, Philippe Giron, Maxim Noeparast, Hugo Vandenplas, Pedro Aza-Blanc, Gustavo J Gutierrez, Jacques De Grève
- Targeting USP13 mediated drug tolerance increases the efficacy of EGFR inhibition of mutant EGFR in Non-Small Cell Lung Cancer(2021)
Authors: Philippe Giron, Carolien Eggermont, Maxim Noeparast, Hugo Vandenplas, Erik Teugels, Ramses Forsyth, Olivier De Wever, Pedro Aza-Blanc, Gustavo J Gutierrez, Jacques De Grève
Pages: 2579-2593 - CRAF mutations in lung cancer can be oncogenic and predict sensitivity to combined type II RAF and MEK inhibition(2019)
Authors: Maxim Noeparast, Philippe Giron, Alfiah Noor, Rajendra Bahadur Shahi, Sylvia De Brakeleer, Carolien Eggermont, Hugo Vandenplas, Bram Boeckx, Diether Lambrechts, Jacques De Grève, et al.
Pages: 5933-5941 - Type II RAF inhibitor causes superior ERK pathway suppression compared to type I RAF inhibitor in cells expressing different BRAF mutant types recurrently found in lung cancer(2018)
Authors: Maxim Noeparast, Philippe Giron, Sylvia De Brakeleer, Carolien Eggermont, Ulrike De Ridder, Erik Teugels, Jacques De Grève
Pages: 16110-16123